Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs United States Oil ETF (USO) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
United States Oil ETFTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs United States Oil ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while United States Oil ETF trades at $126.73. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.

BIOUSO
Market Cap
$9.39B
Sector
Health
52-Week High
$356.25$152.96
52-Week Low
$241.71$66.17
Enterprise Value
$9.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

United States Oil ETF

USO trades at $117.98, down 0.75% amid bearish technical signals with 13 sell indicators versus 4 buy signals. The stock faces pressure from Middle East tensions affecting oil markets, though RSI levels suggest potential oversold conditions. Recent news highlights ongoing Strait of Hormuz deadlock and declining Strategic Petroleum Reserve levels, creating volatility in energy sector valuations.

The outlook remains cautious with technical weakness and geopolitical uncertainty weighing on sentiment. Investment opportunity exists for contrarian buyers given oversold RSI levels, but risks include prolonged Middle East tensions and oil price volatility. Fundamental analysis is limited without current financial ratios available.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About United States Oil ETF

This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.

Read more on USO